---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-000523"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-01-12T23:59:59+00:00"
generated_at: "2026-06-07T00:11:48.120809+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics receives Nasdaq delisting notice; appoints interim CFO Lawrence Hoffman

## Summary
- Nasdaq notified Tenax on Jan 11, 2024 that it fails minimum 500,000 publicly held shares after 1-for-80 reverse split.
- Company has until Feb 26, 2024 to submit a compliance plan; no immediate effect on listing or trading.
- Lawrence Hoffman appointed Interim CFO effective Jan 11, 2024, succeeding Eliot Lurier (deceased).
- Hoffman will be paid $416/hour through Danforth Advisors consulting agreement.

## SEC filing metadata
- accession: 0001654954-24-000523
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-01-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/0001654954-24-000523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-000523
- JSON: https://secwatch.observer/filing/0001654954-24-000523.json
- Plain text: https://secwatch.observer/filing/0001654954-24-000523.txt

## Key facts
- Listing & Compliance Notices
  TENAX THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Rules: 5550(a)(4)
  source text: January 11, 2024, Tenax Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) regarding compliance with Nasdaq Listing Rule 5550(a)(4) (the “Rule”) which requires the Company to have a minimum of 500,000 publicly held shares. The letter from Nasdaq indicated that according to its calculations, as of January 3, 2024, the day after the Company effected a 1-for-80 reverse split of its common stock, the Company no longer meets the requirements of the Rule. This notice of noncompliance has no immediate impact on the cont
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/0001654954-24-000523-index.htm
- Executive change
  Eliot M. Lurier departed as Chief Financial Officer at TENAX THERAPEUTICS, INC..
  - Action: passed away
  - Role: Chief Financial Officer
  source text: Mr. Hoffman succeeds Eliot M. Lurier, who passed away in December 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/0001654954-24-000523-index.htm
- Executive change
  Lawrence R. Hoffman was appointed as Interim Chief Financial Officer at TENAX THERAPEUTICS, INC..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: On January 9, 2024, the Company’s Board of Directors (the “Board”) appointed Lawrence R. Hoffman as Interim Chief Financial Officer of the Company effective January 11, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/0001654954-24-000523-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.